Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Endo Biologics Limited has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 3 pending office actions are assigned to distinct examiners. The prosecution activity occurs across 3 distinct art units. This distribution across 3 distinct art units indicates that each case is handled within a different technical group.
TSAY, MARSHA M is the busiest examiner for the company. This examiner is responsible for 1 pending office action. The 1 pending office action is part of the work currently active in the Biotechnology & Pharmaceuticals technology area. The distinct examiners and the 3 distinct art units provide the technical review for the portfolio.
Practitioners should note the specific requirements of the distinct examiners and the 3 distinct art units involved. The 3 pending office actions represent the current volume of ongoing legal work. TSAY, MARSHA M and the other examiners manage the prosecution for the company. The Biotechnology & Pharmaceuticals technology area is the focus for these filings.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (33%) |
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TSAY, MARSHA M | 1 | 45.5% | +52.8% |
| DICKENS, AMELIA NICOLE | 1 | 47.2% | +21.6% |
| BARRON, SEAN C | 1 | 52.7% | +30.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18763509 | COMPOSITIONS AND METHODS FOR PRODUCING CLOSTRIDIAL COLLAGENASES | BARRON, SEAN C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19288143 | Methods Of Treating Plantar Fibromatosis | TSAY, MARSHA M | — |
| 19174127 | Treatment Of Uterine Fibroids Using Purified Collagenase | DICKENS, AMELIA NICOLE | — |
| 18763509 | COMPOSITIONS AND METHODS FOR PRODUCING CLOSTRIDIAL COLLAGENASES | BARRON, SEAN C | — |
| Art Unit | Apps |
|---|---|
| 1656 | 1 |
| 1645 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19288143 | Methods Of Treating Plantar Fibromatosis | TSAY, MARSHA M | 1656 | §103 | Non-Final OA | — | Pending | Aug 01, 2025 |
| 19174127 | Treatment Of Uterine Fibroids Using Purified Collagenase | DICKENS, AMELIA NICOLE | 1645 | §103§112DP | Non-Final OA | — | Pending | Apr 09, 2025 |
| 18763509 | COMPOSITIONS AND METHODS FOR PRODUCING CLOSTRIDIAL COLLAGENASES | BARRON, SEAN C | 1653 | §101 | Final Rejection | — | Pending | Jul 03, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEndo Biologics Limited has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Marsha M Tsay has the most, with 1 of Endo Biologics Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
